You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Express Scripts

Last Updated: January 16, 2021

DrugPatentWatch Database Preview

Drugs in Development Information for DSM265

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

What is the development status for investigational drug DSM265?

DSM265 is an investigational drug.

There have been 7 clinical trials for DSM265. The most recent clinical trial was a Phase 2 trial, which was initiated on January 1st 2016.

The most common disease conditions in clinical trials are Malaria, Malaria, Falciparum, and Malaria, Vivax. The leading clinical trial sponsors are Medicines for Malaria Venture, AbbVie, and Q-Pharm Pty Limited.

There are two US patents protecting this investigational drug and thirty-six international patents.

Recent Clinical Trials for DSM265
Malaria: Relative Bioavailability and Food Effect of DSM265AbbViePhase 1
Malaria: Relative Bioavailability and Food Effect of DSM265Medicines for Malaria VenturePhase 1
Bioavailability and Effect of Food on DSM265 Granules in Healthy Adult SubjectsAbbViePhase 1

See all DSM265 clinical trials

Clinical Trial Summary for DSM265

Top disease conditions for DSM265
Top clinical trial sponsors for DSM265

See all DSM265 clinical trials

US Patents for DSM265

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
DSM265   Start Trial Antimalarial agents that are inhibitors of dihydroorotate dehydrogenase BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (Austin, TX) MMV MEDICINES FOR MALARIA VENTURE (Geneva, CH) UNIVERSITY OF WASHINGTON (Seattle, WA)   Start Trial
DSM265   Start Trial Substituted 2-alkyl-1-OXO-N-phenyl-3-heteroaryl-1,2,3,4-tetrahydroisoquinoline-4-carb- oxamides for antimalarial therapies ST. JUDE CHILDREN'S RESEARCH HOSPITAL (Memphis, TN) MMV MEDICINES FOR MALARIA VENTURE (Geneva, CH) RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (New Brunswick, NJ)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for DSM265

Drugname Country Document Number Estimated Expiration Related US Patent
DSM265 Brazil BR112012007179 2029-09-29   Start Trial
DSM265 Canada CA2775354 2029-09-29   Start Trial
DSM265 China CN102741255 2029-09-29   Start Trial
DSM265 Cyprus CY1115915 2029-09-29   Start Trial
DSM265 Denmark DK2483274 2029-09-29   Start Trial
DSM265 European Patent Office EP2483274 2029-09-29   Start Trial
DSM265 Spain ES2527835 2029-09-29   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.